Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly EPS (Weighted Average and Diluted) of -$6.28 in Q1 2026, down 36.52% quarter-over-quarter from -$4.6 in Q4 2025, and down 177.88% on a YoY basis from $8.06 in Q1 2025.
Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Scilex Holding's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$6.28 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 177.88% year-over-year to -$6.28; the TTM figure through Mar 2026 stood at -$40.47 (down 598.96% YoY), while the FY2025 annual figure was -$36.48, down 353.17% from the prior year.
- EPS (Weighted Average and Diluted) was -$6.28 for Q1 2026 at Scilex Holding, down from -$4.6 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.72 in Q4 2024 to a low of -$22.17 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$3.3 across 5 years, with a median of -$0.58 in 2024.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 1988.0% in 2024; the steepest drop was 3936.84% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.13 in 2022, then sank by 92.31% to -$0.25 in 2023, then surged by 1988.0% to $4.72 in 2024, then sank by 197.46% to -$4.6 in 2025, then tumbled by 36.52% to -$6.28 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$6.28 (Q1 2026), -$4.6 (Q4 2025), and -$22.17 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.31 |
| 10 | Scilex Holding | - | - | 4.15 Mn | -6.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.28 |
| Dec 31, 2025 | -4.60 |
| Sep 30, 2025 | -22.17 |
| Jun 30, 2025 | -7.42 |
| Mar 31, 2025 | -2.26 |
| Dec 31, 2024 | 4.72 |
| Sep 30, 2024 | -0.58 |
| Jun 30, 2024 | -7.67 |
| Mar 31, 2024 | -8.33 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.63 |
| Jun 30, 2023 | -0.19 |
| Mar 31, 2023 | -0.22 |
| Dec 31, 2022 | -0.13 |
| Sep 30, 2022 | 0.16 |
| Jun 30, 2022 | -0.13 |
| Mar 31, 2022 | -0.07 |
| Dec 31, 2021 | -0.65 |
| Sep 30, 2021 | -0.08 |
| Jun 30, 2021 | -0.01 |